Skip to content
HealthyStudy
Menu

MigraineTwo labels compared

Nurtec vs Qulipta

Nurtec and Qulipta are both gepants and answer different questions. Qulipta is a daily preventive tablet and nothing else. Nurtec is an as-needed attack tablet that also holds a preventive indication at every-other-day dosing. The overlap - prevention - is where the two labels are worth reading closely. This page does that.

Nurtec ODT

Ingredient
Rimegepant
Approved for
Acute treatment of migraine, and prevention of episodic migrainecovers migraine
Supply
Prescription
Boxed warning
None
Pharmacy cost
$128.75 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter
Pfizer Laboratories Div Pfizer Inc. Label version 32, effective 4 June 2026.

Qulipta

Ingredient
Atogepant
Approved for
Preventive treatment of migrainecovers migraine
Supply
Prescription
Boxed warning
None
Pharmacy cost
$38.41 per tablet, capsule or pen, brandwhat pharmacies pay to buy it, not the price at the counter
AbbVie Inc.. Label version 19, effective 30 September 2025.
01From the FDA label

Side by side, straight from the labels

Generated from the two source labels, not typed out by hand, so it cannot drift from what the regulator approved. Rows where both labels say exactly the same thing are marked.

Active ingredientNurtec ODTRimegepantCGRP receptor antagonist (gepant)QuliptaAtogepantCGRP receptor antagonist (gepant)
Approved forNurtec ODTAcute treatment of migraine, and prevention of episodic migraineQuliptaPreventive treatment of migraine
Supplysame in bothNurtec ODTPrescriptionQuliptaPrescription
What pharmacies payAcquisition cost, not retailNurtec ODT$128.75 per tablet, capsule or pen, brandQulipta$38.41 per tablet, capsule or pen, brand
Boxed warningsame in bothNurtec ODTNoneQuliptaNone
What the FDA approved it forNurtec ODT
  • acute treatment of migraine with or without aura in adults
  • preventive treatment of episodic migraine in adults Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults. Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.
Qulipta
  • QULIPTA is indicated for the preventive treatment of migraine in adults.
  • QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of migraine in adults.
Forms and strengthsNurtec ODT
  • Orally disintegrating tablets: white to off-white, circular, and debossed with the symbol, each containing 75 mg of rimegepant.
  • NURTEC ODT orally disintegrating tablets: 75 mg
Qulipta
  • QULIPTA 10 mg is supplied as white to off-white, round biconvex tablets debossed with "A" and "10" on one side.
  • Tablets: 10 mg, 30 mg, and 60 mg.
How the label says it is takenNurtec ODT
  • Recommended dosage for acute treatment of migraine: 75 mg taken orally, as needed.
  • The safety of using more than 18 doses in a 30-day period has not been established.
  • Recommended dosage for preventive treatment of episodic migraine: 75 mg taken orally every other day.
  • The maximum dose in a 24-hour period is 75 mg.
  • NURTEC ODT can be taken with or without food. Recommended Dosing for Acute Treatment of Migraine The recommended dose of NURTEC ODT is 75 mg taken orally, as needed. The maximum dose in a 24-hour period is 75 mg. The safety of using more than 18 doses in a 30-day period has not been established. NURTEC ODT can be taken with or without food.
Qulipta
  • QULIPTA is taken orally with or without food.
  • For episodic migraine, the recommended dosage is 10 mg, 30 mg, or 60 mg taken once daily.
  • For chronic migraine, the recommended dosage is 60 mg taken once daily.
  • Severe Renal Impairment or End-Stage Renal Disease: Episodic migraine: 10 mg once daily. Chronic migraine: Not recommended.
Most common adverse reactionsNurtec ODT
  • most common adverse reaction in Study 1 was nausea (2% in patients who received NURTEC ODT compared to 0.4% of patients who received placebo).
  • most common adverse reactions (occurring in at least 2% of rimegepant-treated patients and at a frequency of at least 1% higher than placebo) in Study 2 were nausea (2.7% in patients who received rimegepant compared with 0.8% of patients who received placebo) and abdominal pain/dyspepsia (2.4% in patients who received rimegepant compared with 0.8% of patients who received placebo).
Qulipta
  • most common adverse reactions (incidence at least 4% and greater than placebo) are nausea, constipation, and fatigue/somnolence.
Warnings and precautionsNurtec ODT
  • Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue NURTEC ODT and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis, dyspnea, and rash, and can occur days after administration.
  • Hypertension: New-onset or worsening of pre-existing hypertension may occur.
  • Raynaud's Phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur. Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis, dyspnea, and rash, have occurred in patients treated with NURTEC ODT. Hypersensitivity reactions can occur days after administration, and delayed serious hypersensitivity has occurred.
Qulipta
  • Hypersensitivity Reactions: If a hypersensitivity reaction occurs, discontinue QULIPTA and initiate appropriate therapy. Severe hypersensitivity reactions have included anaphylaxis and dyspnea. These reactions can occur days after administration.
  • Hypertension: New-onset or worsening of pre-existing hypertension may occur.
  • Raynaud's phenomenon: New-onset or worsening of pre-existing Raynaud's phenomenon may occur.
ContraindicationsNurtec ODT
  • NURTEC ODT is contraindicated in patients with a history of hypersensitivity reaction to rimegepant, NURTEC ODT, or any of its components.
  • Reactions have included anaphylaxis and delayed serious hypersensitivity.
Qulipta
  • QULIPTA is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of QULIPTA.
  • Reactions have included anaphylaxis and dyspnea.
Drug interactionsNurtec ODT
  • Strong CYP3A4 Inhibitors: Avoid concomitant administration.
  • Moderate CYP3A4 Inhibitors: Avoid another dose within 48 hours when administered with a moderate CYP3A4 inhibitor.
  • Strong and Moderate CYP3A Inducers: Avoid concomitant administration.
  • Potent Inhibitors of P-gp: Avoid another dose of NURTEC ODT within 48 hours when administered with a potent P-gp inhibitor. CYP3A4 Inhibitors Concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4 results in a significant increase in rimegepant exposure. Avoid concomitant administration of NURTEC ODT with strong inhibitors of CYP3A4.
Qulipta
  • Recommended dosage modifications: Strong CYP3A4 Inhibitors:
  • Episodic or chronic migraine: 10 mg once daily Strong CYP3A4 Inducers:
  • Episodic migraine: 60 mg once daily (monitor for reduced efficacy).
  • Chronic migraine: Not recommended.
  • Moderate CYP3A4 Inducers:
  • Episodic migraine: 60 mg once daily.
Label versionNurtec ODT4 June 2026Qulipta30 September 2025
02Written by us

One document covers two jobs, the other covers one

The Nurtec label covers acute treatment of migraine and preventive treatment of episodic migraine. The Qulipta label covers preventive treatment of migraine only - but in both flavours, with dosing for episodic migraine at 10, 30 or 60 mg once daily and for chronic migraine at 60 mg once daily.

Read side by side: for chronic migraine prevention only Qulipta's label speaks; for stopping an attack only Nurtec's does; for episodic migraine prevention both do, on different schedules.

03Written by us

Every other day against every day

Nurtec's preventive schedule is 75 mg every other day. Qulipta's is daily, with the dose picked from three strengths. The two handle drug interactions differently as well: Qulipta's label lowers the dose to 10 mg with strong CYP3A4 inhibitors, while Nurtec's advises avoiding concomitant use with them altogether.

04Written by us

What this page does not tell you

It does not say whether prevention or acute treatment is the right strategy for anyone, or which gepant to pick. Those decisions belong to a clinician; the labels describe what was approved, and this page stops where they stop.

05Written by us

Common questions

Can Qulipta stop an attack the way Nurtec can?
Acute treatment is not among Qulipta's indications: its label covers preventive treatment of migraine. Nurtec's label covers both acute treatment and prevention of episodic migraine.
Which one covers chronic migraine?
Qulipta: its label sets 60 mg once daily for chronic migraine. Nurtec's preventive indication is for episodic migraine.
Are both from the same class?
Yes, both labels describe CGRP receptor antagonists - gepants. Neither carries a boxed warning, and neither has the cardiovascular contraindications of the triptans.
06

Sources

Every fact above comes from one of these documents. The date is the effective date of the label version this page was built from.

Each stripe is one section of the label, each division in a stripe one entry in that section.

07

Other comparisons in this category

Page last updated 29 August 2026

Compiled by the HealthyStudy editorial team from FDA source documents. No medical reviewer is credited on this page, because none reviewed it.